Earlier this month, Mumbai-based brokerage Ambit Capital published an Expert White Paper on pharmaceuticals in which it observed that the US Food & Drug Administration's decision to conduct surprise inspections at Indian manufacturing sites (as opposed to inspections with prior notice) has "raised regulatory risks" at Indian companies. The US FDA has been under pressure … Continue reading Mitigating regulatory risk at Indian Pharma
Apothecurry 